CoChat

Rapid Increase in Pertactin-deficient Bordetella pertussis Isolates, Australia

Open access
Lam, Connie, Octavia, Sophie, Ricafort, Lawrence, Sintchenko, Vitali, Gilbert, Gwendolyn L., Wood, Nicholas, McIntyre, Peter, Marshall, Helen, Guiso, Nicole, Keil, Anthony D., Lawrence, Andrew, Robson, Jenny, Hogg, Geoff, Lan, Ruiting · 2014 · Emerging Infectious Diseases
Cited by 173

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Acellular vaccines against Bordetella pertussis were introduced in Australia in 1997.By 2000, these vaccines had replaced whole-cell vaccines.During 2008-2012, a large outbreak of pertussis occurred.During this period, 30% (96/320) of B. pertussis isolates did not express the vaccine antigen pertactin (Prn).Multiple mechanisms of Prn inactivation were documented, including IS481 and IS1002 disruptions, a variation within a homopolymeric tract, and deletion of the prn gene.The mechanism of lack of expression of Prn in 16 (17%) isolates could not be determined at the sequence level.These findings suggest that B. pertussis not expressing Prn arose independently multiple times since 2008, rather than by expansion of a single Prnnegative clone.All but 1 isolate had ptxA1, prn2, and ptxP3, the alleles representative of currently circulating strains in Australia.This pattern is consistent with continuing evolution of B. pertussis in response to vaccine selection pressure. B ordetella pertussis is the gram-negative coccobacil-lus that causes the respiratory disease pertussis, also known as whooping cough.The incidence of pertussis infection and related deaths decreased dramatically after implementation of immunization with a whole-cell vaccine (WCV) during the 1950s.Because of side effects of WCV, such as high rates of fever and local reactions, and variable efficacy of WCVs, a less reactogenic acellular vaccine (ACV) was developed in the 1980s.ACVs have now replaced WCVs in many industrialized countries for primary and booster vaccinations against pertussis.Although ACV formulations differ in the number of component pertussis antigens, the vaccine used in Australia contains pertussis toxin (Ptx), pertactin (Prn), and filamentous hemagglutinin (Fha).A 5-component (Ptx, Prn, Fha, fimbrial antigen [Fim] 2, and Fim3) ACV is used for short periods in some regions (1).ACVs were introduced for the fourth and fifth doses in most states in Australia during 1997 and for all doses during 1999 (Figure 1).South Australia introduced ACVs for all doses in 1997.The current vaccination schedule for pertussis comprise 3 primary doses of ACV at 2, 4, and 6 months of age, and a booster vaccination at 4 years of age.A booster vaccination with ACV at 18 months of age, which was introduced in 1985, was removed from the National Immunization Program in Australia in 2003, and an adult-formulated ACV was introduced for children at 12-17 years of age in school-based programs in 2004 (2,3).Since 1991, data on reported pertussis cases show that outbreaks occurred in Australia in 1996-1997, 2001, and 2004, and a series of outbreaks occurred in different regions starting in 2008 (Figure 1) (2,3).Multiple factors probably contributed to the resurgence of pertussis in highincome countries that had long-standing pertussis immunization programs.These factors include waning immunity (exacerbated by the change from WCVs to ACVs and, in Australia, cessation of the booster vaccination at 18 months Rapid Increase in Pertactin-deficient Bordetella pertussis Isolates, Australia

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3201/eid2004.131478

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Lam, C., Octavia, S., Ricafort, L., Sintchenko, V., Gilbert, G. L., Wood, N., McIntyre, P., Marshall, H., Guiso, N., Keil, A. D., Lawrence, A., Robson, J., Hogg, G., & Lan, R.
Venue
Emerging Infectious Diseases
Published
2014-04
Volume
20
Issue
4
Pages
626-33
ISSN
  • 1080-6040 (ISSN-L)
  • 1080-6059
OpenAlex
W2018942826
Cited by
173
References
1
FWCI
18.52
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.